MetaCap

Gain Therapeutics (GANX) vs RenovoRx (RNXT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

RenovoRx (RNXT) has outperformed Gain Therapeutics (GANX) over the past year, gaining 18.3% versus a loss of 62.4%. Over five years, RNXT leads with a -85.3% price change compared with -87.3% for GANX. RenovoRx is the larger company by market cap ($45.5 million vs $44.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GANX-62.43%RNXT+18.34%
+231%+76%-79%
Nov 21, 20251 yearNov 20, 2026
GANX-87.92%RNXT-85.71%
+5%-45%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GANX versus RNXT key metrics
MetricGANXRNXT
Share price$0.9994$0.942
Market cap$44.50M$45.45M
1-day change-4.82%-10.29%
YTD return-68.96%+12.14%
1-year return-62.43%+18.34%
5-year return-87.27%-85.26%
EPS (TTM)$-0.42$-0.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.12M
Revenue growth (YoY)—+2511.63%
Net income (latest FY)$-20.16M$-11.17M
Gross margin—70.88%
Operating margin—-1113.98%
Net margin—-994.48%
52-week high$4.34$2.59
52-week low$0.94$0.77
Distance from 52-week high-76.97%-63.63%
Analyst consensusstrong_buynone
Avg. price target upside+620.43%+656.90%
Average volume550.22K815.75K
Shares outstanding44.53M48.25M
Employees2017
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RNXT has outperformed GANX by 80.8 percentage points over the past year.

About Gain Therapeutics

GANX stock →

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

About RenovoRx

RNXT stock →

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

GANX vs RNXT FAQ

Which is bigger, Gain Therapeutics or RenovoRx?

RenovoRx (RNXT) is larger, with a market capitalization of $45.45M compared with $44.50M for Gain Therapeutics (GANX).

Which stock has performed better over the past year, GANX or RNXT?

RNXT returned +18.34% over the past 12 months, compared with -62.43% for GANX (price return, excluding dividends). Past performance does not predict future results.

Are Gain Therapeutics and RenovoRx in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons